药品注册申请号:007073
申请类型:NDA (新药申请)
申请人:PFIZER
申请人全名:PFIZER INC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 AZULFIDINE SULFASALAZINE TABLET;ORAL 500MG Yes Yes AB 1950/06/20 Approved Prior to Jan 1, 1982 Prescription
002 AZULFIDINE EN-TABS SULFASALAZINE TABLET, DELAYED RELEASE;ORAL 500MG Yes Yes AB 1983/04/06 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2022/11/16 SUPPL-133(补充) Approval Labeling STANDARD
2021/11/01 SUPPL-130(补充) Approval Labeling STANDARD
2021/01/15 SUPPL-129(补充) Approval Labeling STANDARD
2015/11/20 SUPPL-127(补充) Approval Manufacturing (CMC) PRIORITY
2014/03/04 SUPPL-128(补充) Approval Labeling STANDARD
2013/07/18 SUPPL-126(补充) Approval Labeling STANDARD
2012/12/12 SUPPL-125(补充) Approval Labeling STANDARD
2009/10/19 SUPPL-124(补充) Approval Labeling STANDARD
2002/11/12 SUPPL-121(补充) Approval Manufacturing (CMC) PRIORITY
2002/07/30 SUPPL-120(补充) Approval Labeling STANDARD
2001/08/17 SUPPL-115(补充) Approval Labeling STANDARD
2001/02/05 SUPPL-117(补充) Approval Manufacturing (CMC) PRIORITY
2000/09/26 SUPPL-118(补充) Approval Labeling STANDARD
2000/08/18 SUPPL-116(补充) Approval Labeling STANDARD
2000/04/25 SUPPL-112(补充) Approval Labeling STANDARD
2000/04/24 SUPPL-109(补充) Approval Labeling STANDARD
2000/04/18 SUPPL-113(补充) Approval Labeling STANDARD
1999/08/13 SUPPL-110(补充) Approval Labeling STANDARD
1997/12/23 SUPPL-107(补充) Approval Manufacturing (CMC) PRIORITY
1996/10/17 SUPPL-102(补充) Approval Labeling STANDARD
1996/07/25 SUPPL-105(补充) Approval Manufacturing (CMC) PRIORITY
1996/06/14 SUPPL-103(补充) Approval Manufacturing (CMC) PRIORITY
1996/06/14 SUPPL-101(补充) Approval Manufacturing (CMC) PRIORITY
1996/03/05 SUPPL-104(补充) Approval Manufacturing (CMC) PRIORITY
1996/02/21 SUPPL-99(补充) Approval Manufacturing (CMC) PRIORITY
1995/09/28 SUPPL-97(补充) Approval Manufacturing (CMC) PRIORITY
1995/05/18 SUPPL-106(补充) Approval Manufacturing (CMC) PRIORITY
1995/03/29 SUPPL-100(补充) Approval Manufacturing (CMC) PRIORITY
1994/12/19 SUPPL-98(补充) Approval Manufacturing (CMC) PRIORITY
1994/06/08 SUPPL-93(补充) Approval Manufacturing (CMC) PRIORITY
1994/06/08 SUPPL-92(补充) Approval Manufacturing (CMC) PRIORITY
1994/06/07 SUPPL-85(补充) Approval Manufacturing (CMC) PRIORITY
1994/01/26 SUPPL-87(补充) Approval Manufacturing (CMC) PRIORITY
1993/11/03 SUPPL-96(补充) Approval Labeling STANDARD
1993/11/02 SUPPL-95(补充) Approval Labeling STANDARD
1993/10/20 SUPPL-94(补充) Approval Manufacturing (CMC) PRIORITY
1993/10/20 SUPPL-84(补充) Approval Manufacturing (CMC) PRIORITY
1993/08/09 SUPPL-89(补充) Approval Manufacturing (CMC) PRIORITY
1993/08/09 SUPPL-88(补充) Approval Manufacturing (CMC) PRIORITY
1993/06/09 SUPPL-86(补充) Approval Manufacturing (CMC) PRIORITY
1993/04/05 SUPPL-91(补充) Approval Labeling STANDARD
1993/04/05 SUPPL-90(补充) Approval Labeling STANDARD
1992/09/22 SUPPL-83(补充) Approval Manufacturing (CMC) PRIORITY
1991/07/10 SUPPL-80(补充) Approval Manufacturing (CMC) PRIORITY
1991/07/10 SUPPL-79(补充) Approval Manufacturing (CMC) PRIORITY
1990/11/07 SUPPL-82(补充) Approval Labeling
1990/11/07 SUPPL-81(补充) Approval Labeling
1985/07/19 SUPPL-74(补充) Approval Manufacturing (CMC) PRIORITY
1985/02/05 SUPPL-71(补充) Approval Labeling
1985/02/05 SUPPL-70(补充) Approval Labeling
1984/05/11 SUPPL-77(补充) Approval Labeling
1983/12/12 SUPPL-76(补充) Approval Labeling
1983/04/06 SUPPL-20(补充) Approval Labeling
1983/04/06 SUPPL-18(补充) Approval Manufacturing (CMC) PRIORITY
1983/04/06 SUPPL-17(补充) Approval Manufacturing (CMC) PRIORITY
1983/01/18 SUPPL-75(补充) Approval Manufacturing (CMC) PRIORITY
1982/07/15 SUPPL-72(补充) Approval Manufacturing (CMC) PRIORITY
1982/07/02 SUPPL-73(补充) Approval Manufacturing (CMC) PRIORITY
1981/06/30 SUPPL-65(补充) Approval Labeling
1981/03/25 SUPPL-64(补充) Approval Labeling
1981/03/25 SUPPL-61(补充) Approval Labeling
1981/03/25 SUPPL-60(补充) Approval Labeling
1981/03/05 SUPPL-54(补充) Approval Manufacturing (CMC) PRIORITY
1950/06/20 ORIG-1(原始申请) Approval Type 1 - New Molecular Entity PRIORITY
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:SULFASALAZINE 剂型/给药途径:TABLET;ORAL 规格:500MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
007073 001 NDA AZULFIDINE SULFASALAZINE TABLET;ORAL 500MG Prescription Yes Yes AB Approved Prior to Jan 1, 1982 PFIZER
080197 001 ANDA SULFASALAZINE SULFASALAZINE TABLET;ORAL 500MG Prescription No No AB Approved Prior to Jan 1, 1982 CHARTWELL
085828 001 ANDA SULFASALAZINE SULFASALAZINE TABLET;ORAL 500MG Prescription No No AB Approved Prior to Jan 1, 1982 WATSON LABS
040349 001 ANDA SULFASALAZINE SULFASALAZINE TABLET;ORAL 500MG Prescription No No AB 2002/01/11 NUVO PHARMS INC
活性成分:SULFASALAZINE 剂型/给药途径:TABLET, DELAYED RELEASE;ORAL 规格:500MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
007073 002 NDA AZULFIDINE EN-TABS SULFASALAZINE TABLET, DELAYED RELEASE;ORAL 500MG Prescription Yes Yes AB 1983/04/06 PFIZER
075339 001 ANDA SULFASALAZINE SULFASALAZINE TABLET, DELAYED RELEASE;ORAL 500MG Prescription No No AB 2002/01/11 NUVO PHARMS INC
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database